REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exo Imaging, Inc., a company pioneering a high-performance ultrasound platform based on patented Piezoelectric Micromachined Ultrasonic Transducers (pMUT) technology and artificial intelligence (AI) for imaging and therapeutic applications, announced a $35M Series B financing round. The company was founded in 2015 and has raised nearly $50M to date. Intel Capital led the Series B. Other investors in Exo include: Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus Venture Partners, OSF Healthcare, Rising Tide Fund, Sony Innovation Fund, and Wanxiang Healthcare Investments.
Exo (pronounced “Echo”) is bringing diagnostic-grade medical imaging to the pocket of every caregiver and clinician worldwide. The company is developing an affordable medical ultrasound platform capable of exceptional image fidelity, penetration depth and 3D imaging that still fits in the palm of your hand.
“For too long, medical imaging products have been expensive, cumbersome to use and have catered to a small segment of users. Our mission is to fundamentally change the economics, usability and accessibility of high-quality medical imaging and therapeutic tools,” said Sandeep Akkaraju, CEO and president at Exo.
The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging.
The founders, Sandeep Akkaraju, chief executive officer; Janusz Bryzek, Ph.D., chairman and chief visionary officer; Yusuf Haque, Ph.D., chief technology officer and senior vice president of engineering; and John Kokulis, chief financial officer, have nearly 20 startups among them, along with several large exits.
“Our goal is to enable every medical practitioner in the world with affordable and easy to use tools that make imaging accessible,” Mr. Akkaraju added. “Our Series B financing will enable us to advance our products through the FDA 510K clearance process and into commercialization. Exo will also use the proceeds to build out its team of engineering, sales, and operations professionals.”
Dave Flanagan, Vice President of Intel Corp. and Senior Managing Director of Intel Capital, noted, “The team at Exo is solving multiple challenges, ranging from fundamental material science to AI, while scaling from low-cost handheld imaging to the highest end equipment. We share their enthusiasm for bringing medical imaging and AI to a much broader audience.” Investment Director Eric King led the investment for Intel Capital and sits on Exo’s board.
About Exo Imaging
Exo is pioneering a high-performance handheld ultrasound platform and AI for imaging and therapeutic applications. Exo is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high quality medical imaging, Exo will empower healthcare professionals to make critical, real-time decisions that improve patient outcomes. For more information, please visit www.exo-imaging.com.
About Intel Capital
Intel Capital invests in innovative startups targeting artificial intelligence, autonomous vehicles, datacenter and cloud, 5G, next-generation compute and a wide range of other disruptive technologies. Since 1991, Intel Capital has invested US$12.5 billion in 1,554 companies worldwide, and 670 portfolio companies have gone public or participated in a merger. Intel Capital curates thousands of business development introductions each year between its portfolio companies and the Global 2000. For more information on what makes Intel Capital one of the world’s most powerful venture capital firms, visit www.intelcapital.com or follow @Intelcapital.
